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Objectives: Many natural compounds have been investigated as drug candidates
to prevent human immunodeficiency virus (HIV) with low cytotoxicity. We tested
whether ingenol from Euphorbia ingens exerts anti-HIV effects in human Tcell lines.
Methods and Results: Ingenol effectively maintained high cell viability
(CD50, >1 mM) in H9 and MT4 T cells. The efficacy of ingenol to inhibit HIV-1
infection was dose dependent. ED50 for 100 and 200 TCID50 of HIV-1 was 5.06
and 16.87 mM, respectively. Gag p24 antigen production in ingenol-treated MT4
cells was reduced by 24.5% on day 6 post-infection. While p24 antigen was reduced
in ingenol-treated cells, levels of cytokines such as TNF-a and IL-6 and chemokines
such as RANTES and MCP-1 were increased. dUTP level related to late apoptotic
events was increased on day 2 post-infection of HIV by ingenol treatment, whereas
expression of annexin V was unchanged. Reduced levels of iNOS and ZAP-70 after
HIV infection were recovered by ingenol treatment.
Conclusion: Ingenol helps T cells to survive longer against viremia after HIV-1
infection, without exerting cytotoxic effects. Ingenol can be considered a safe and
efficacious candidate for immune-boosting therapy for AIDS patients.1. Introduction
Chemotherapy using natural products extracted from
various resources, including plants and microorganisms,
has long been of interest in the study of anti-human
immunodeficiency virus (HIV) drug development [1,2].
Many natural compounds have been widely tested, and
some have been reported as possible candidates for
inhibition of HIV replication or boosting of hostibuted under the terms o
y-nc/3.0) which permits unr
is properly cited.
anuscript.
ol and Prevention. Publisheimmune response. They are mostly secondary metabo-
lites, including terpenoids and polyphenols. Natural
compounds can provide novel anti-AIDS chemothera-
peutic leads that are structurally unique or have new
mechanisms of action [3].
The chemical constituents of some species of
Euphorbia, which are succulent plants growing mostly
in semi-desert areas, have been found to include che-
motaxonomically important myrsinane diterpenoidsf the Creative Commons Attribution Non-Commercial License
estricted non-commercial use, distribution, and reproduction in
d by Elsevier. All rights reserved.
Figure 1. Chemical structure of ingenol.
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urease, HIV-1 reverse transcriptase, and prolyl endo-
peptidase [4]. Ingenol, one of the active ingredients in
an extract from Euphorbia peplus, was shown to have
activity against human melanoma cells and the ability to
induce the apoptosis-regulating tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) in
preclinical study [5]. While latex as well as total leaf
extracts of Euphorbia plants exhibit EpsteineBarr virus
(EBV) inducing activity [6], some ingenol derivatives
were reported as potential HIV reverse transcriptase
inhibitors [7].
Ingenol derivatives are structurally close to phorbol
12-myristate 13-acetate (PMA) [8], but have been less
studied than PMA because of their structural
complexity. Prostratin [9], another nontumorigenic
phorbol ester, was reported to have HIV-inhibitory
activity related to PKC activation [10]. PMA itself
also showed inhibitory effects against HIV-1 [11]. Other
reports have indicated that treatment of ingenol deriva-
tives such as ingenol triacetate and aurintricarboxylic
acid in HIV-infected T cells inhibited HIV replication
through downregulation of CD4 receptors [12,13] and
CXCR4 receptors [10].
We tested the anti-HIV activity of ingenol purified
from Euphorbia ingens and subsequent viral and host
event-influencing immune responses, which remain
largely unknown despite some previous work on
ingenol’s antiviral [12,14] and anti-inflammatory effects
[15,16]. In addition to anti-HIV activity screening, it is
essential to understand the mechanism of action related
to HIV inhibition or immune response during ingenol
action against infection, which might contribute to
developing novel anti-HIV reagents or new therapeutic
strategies for AIDS.2. Materials and Methods
2.1. Cells culture and reagents
MT4 and H9 human T lymphocyte cell lines were
obtained from the NIH AIDS Research and Reference
Reagent Program (Bethesda, MD). Cells were main-
tained in RPMI-1640 medium (GIBCO, Carlsbad, NY)
supplemented with 10% fetal bovine serum, penicillin
100 U/mL, streptomycin 100 mg/mL, and glutamine
2 mM.
Ingenol (Figure 1) purified from E. ingens was
obtained from Sigma-Aldrich (St. LouisMO). Compound
was dissolved in dimethylsulfoxide (DMSO) and further
diluted with RPMI-1640medium. The final concentration
of DMSO in stock solution was <1.5% (v/v).
2.2. Preparation of virus stock and titration
To obtain HIV-1 virus stock we incubated HTLV-
IIIB/H9 cells (CRL 8543; American Type Culture
Collection, Manassas, VA) for 14 days and harvested cellculture supernatants twice/week. The virus was then
harvested from cell culture supernatant by centrifugation
at 4500 rpm for 20 minutes followed by filtration through
0.22-mm filter (Millipore, Bedford, MA). To quantify
viable HIV-1 virions in culture supernatant we evaluated
50% tissue culture infectious dose (TCID50) using HIV-1
gag p24 antigen ELISA (BioMerieux, Durham, NC).
Titration for TCID50 infectivity was measured by the
Spearman-Karber statistical method. The titer of virus
stock was determined in MT4 cells (6.56  105 TCID50/
mL) then divided into aliquots of fixed volume. Prepared
viruses were stored at e80C until use.
2.3. Cytotoxicity and anti-HIV activity assay
Cytotoxicity of ingenol was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
method (MTT assay; Roche, Basel, Switzerland) after
24-h incubation using MT4 and H9 cells. Anti-HIV
infection activity was measured by cell viability of
infected MT4 cells on day 6 postinfection of HIV-1 in
the presence of serially diluted ingenol (0.1e250 mM).
MT4 cells were infected with HIV-1 at various multi-
plicities of infection (MOI; 0.002e0.016 [25e200
TCID50]). The 50% effective dose (ED50) was calcu-
lated based on inhibition of virus-induced cell death
after HIV infection, and 50% cytotoxic dose (CD50) was
calculated based on reduction of viability in noninfected
cells. Absorbance was measured at 550 nm wavelength
with 690 nm reference wavelength using Bio-Tek
microplate reader (EL800; Winooski, VT).
2.4. HIV-1 p24 antigen ELISA assay and
luminex assay for cytokine measurement
MT4 cells were infected with HIV-1 at 0.004 MOI
(50 TCID50) after treatment of 5 mM ingenol. Gag p24
antigen level in culture supernatant was measured by
Vironostika HIV-1 Antigen MicroELISA kit (Bio-
Merieux, Durham, NC). Absorbance was read at 450 nm
wavelength using EL800 Bio-Tek microplate reader.
Cytokine and chemokine levels in culture superna-
tants were measured at the same day of p24 antigen
measurement. Procarta human cytokine 5-plex kit and
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from Parnomics (Fremont, CA); assay was performed
following the manufacturer’s protocol. Results were
read using Bio-Plex 200 Suspension array system (Bio-
Rad, Hercules, CA) and calculated with Bio-Plex
Manager software 4.1 (Bio-Rad).
2.5. Flow cytometric assay
Cells were incubated with Golgi-Plug (BD
Biosciences, San Jose, CA) for 4 hours and per-
meabilized with PermFix/PermWash (BD Biosciences).
Then, cells were stained using Annexin V-Mitotracker
Vybrant Apoptosis assay kit (Molecular Probes,
Eugene, OR) and APO-BrdUTM TUNEL assay kit
(Invitrogen, Carlsbad, CA) following the manufacturers’
protocols. Stained cells were analyzed by FC500 flow
cytometer (Beckman Coulter, Fullerton, CA).
2.6. Western blot analysis
Cellular lysate was prepared using ice-cold RIPA
buffer (50 mM Tris pH 7.5, 0.5% deoxycholate, 0.5%
NP-40, 0.5% SDS, and 100 mM NaCl) supplemented
with freshly added protease inhibitor cocktail. Protein
concentration in cell lysate was determined by BCA
protein assay kit (Pierce, Rockford, IL); proteins were
separated by SDS-PAGE. After transfer of separated
proteins to ImmobiloneP PVDF membrane (Milli-
pore, Danvers, MA), primary antibodies were applied
for hybridization: rabbit anti-human inducible nitric
oxide synthase (iNOS) antibody (Abcam, Cambridge,
MA) and rabbit anti-human zeta chain-associated
protein kinase 70 (ZAP-70) antibody (Cell Signaling,
Danvers, MA). Hybridized bands were developed with
HRP-conjugated anti-rabbit secondary antibody. b-
Actin antibody was used as a loading control, TMB
chemiluminescence substrate for visualization.Figure 2. Ingenol revealed low cytotoxicity and dose-dependent
a tetrazolium-based colorimetric method (MTT). (A) Ingenol revea
cells were allowed to proliferate for 24 hours in the presence of
measured on day 6 postinfection. MT4 cells were infected with HIV
TCID50]) with 1.95e250 mM ingenol. Data represent means  SD2.7. Statistical analysis
Data are expressed as mean  SD. Student’s t test
was used to analyze significance of differences between
test and control. Statistical significance was set at p <
0.05.3. Results
3.1. Ingenol exerts low cytotoxicity and dose-
dependent anti-HIV infection activity
Ingenol revealed no toxic effects in MT4 cells and
comparatively low cytotoxicity in H9 cells at the range
0.1e100 mM (Figure 2A). Survival of MT4 cells was
more stable up to high concentration than that of H9
cells (Figure 2A).
Cell viability after HIV infection in MT4 cells pre-
incubated with ingenol at concentrations 1.95e250 mM
was observed as a dose- and MOI-dependent pattern
around day 6 postinfection (Figure 2B). ED50 for 100
and 200 TCID50 of HIV-1 was 5.06 and 16.87 mM,
respectively. This dose-dependent anti-HIV infection
activity of ingenol was similar to that of azidothymidine
(AZT), which is widely used for AIDS treatment (data
not shown).
3.2. Ingenol reduced HIV-1 gag p24 antigen
production by inducing cytokines and
chemokines
Gag p24 antigen production in HIV-infected MT-4
cells when 5 mM ingenol was treated into cell culture
media was reduced by approximately 25% on day 6
postinfection (Figure 3A).
Th1 cytokines such as TNF-a and IL-6 were highly
induced by ingenol treatment in HIV-infected MT4
cells, whereas Th2 cytokines were not detectedanti-HIV infection activity. Viable cells were counted using
led good cell viability in MT4 cells and H9 cells. MT4 and H9
serially diluted ingenol. (B) Anti-HIV infection activity was
-1IIIB at multiplicity of infection (MOI; 0.002e0.016 [25-200
of three independent experiments.
Figure 3. Ingenol treatment reduced Gag p24 production,
whereas cytokines and chemokines were induced during HIV
infection after ingenol treatment. MT4 cells were infected with
HIV-1IIIB at multiplicity of infection (MOI; 0.004 [50 TCID50])
after treatment with 5 mM ingenol and supernatants analyzed
every 3 days thereafter . (A) p24 antigen production measured
by ELISA showed reduced level by ingenol treatment. (B)
Cytokine production including TNF-a and IL-6 was induced by
ingenol during HIV infection at day 6 postinfection. (C) Che-
mokine production was induced by ingenol during HIV infec-
tion at day 6 postinfection. RANTES and MIP-1a were highly
increased whereas MIP-1b, MCP-1, and eotaxin were moder-
ately or slightly increased by ingenol treatment. Data represent
means  SD of three independent experiments.
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times and IL-6 was also induced by ingenol treatment.
Chemokines such as RANTES and MIP-1a were
remarkably induced by ingenol treatment in HIV-infectedcells on day 6 postinfection of HIV (Figure 3C). MIP-1b,
MCP-1, and eotaxin were moderately increased or
recovered by ingenol treatment compared with HIV-
infected cells without ingenol (Figure 3C).
3.3. Apoptosis more advanced to late phase by
ingenol in HIV-infected cells
Percent apoptotic events MT4 cells was measured by
flow cytometric assay using annexin V as an early phase
marker and dUTP as a late phase marker at 24 h post-
infection. Annexin-V expression was slightly reduced
by 4% in ingenol-treated MT4 cells compared with
nontreated cells; however, the change was not statisti-
cally significant (Figure 4A). The dUTP level in HIV-
infected MT4 cells was further increased by 25% with
ingenol treatment (Figure 4B).
3.4. iNOS and ZAP-70 recovered by ingenol
treatment in HIV-infected cells
Western blot results of iNOS and ZAP-70 expression
are shown in Figure 5. Total cell lysate was analyzed at
24 h postinfection; both iNOs and ZAP-70 were
recovered by ingenol treatment compared with the
remarkably reduced levels of HIV infection. Especially,
iNOS was increased to a higher level than that in
uninfected cells, whereas ZAP-70 recovered to almost
the same level of uninfected cells.4. Discussion
Ingenol and its derivatives are known to have several
biological activities. In particular, they have a degree of
potential to activate protein kinase C (PKC) [17]. In
previous studies, some ingenol derivatives were
demonstrated to be potent inhibitors of acutely HIV-
infected cells [12], whereas others were potent activa-
tors of HIV-1 transcription in chronically infected cells
[7]. We focused on the antieHIV-1 activity of ingenol,
so as further to elucidate the mechanism of inhibition,
and to identify cellular factors related to inhibition of
HIV-1 replication in infected cells.
Ingenol-treated MT4 cells showed reduced p24
level compared with PBS-treated HIV-infected cells on
day 6 postinfection. Gag p24 antigen of ingenol-treated
cells was reduced by approximately 25% compared
with mock-infected cells. Cell survival of ingenol-
treated MT4 cells on day 6 postinfection was reduced
to approximately 20% lower than AZT control (data
not shown). Although our results showed lower inhi-
bition of HIV infectivity compared with AZT, we
nonetheless observed significant anti-HIV activity of
ingenol.
HIV-1 induces apoptotic and anti-apoptotic signaling
in infected and uninfected T lymphocytes, and thereby
counteracts the antiviral response and immune effector
cell functions [18]. Excessive induction of apoptosis
Figure 4. Late apoptotic events induced by ingenol during HIV infection. MT4 cells were infected with HIV-1IIIB at multiplicity
of infection (MOI; 0.004 [50 TCID50]) after addition of 5 mM ingenol into culture media, and cells were analyzed using flow
cytometry at 24 hours postinfection. (A) Annexin V expression as early apoptotic marker analyzed by flow cytometry. (B) dUTP
level as late apoptotic marker investigated by flow cytometry using BrdU staining. Bar graphs on the right side represent calculated
ratio of annexin Ve or dUTP-expressing cells. Data represent means  SD of three independent experiments.
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response and favor pathogen immune evasion [19].
Annexin V binding of ingenol-treated cells was
reduced by approximately 4% compared with nontreatedFigure 5. Western blot analysis of iNOs and ZAP-70 in MT4
cells. Ingenol treatment during HIV infection resulted in
recovery of iNOS and ZAP-70. MT-4 cells were infected with
HIV-1IIIB at multiplicity of infection (MOI; 0.004 [50
TCID50]) after 5 mM ingenol treatment then protein expression
in cell lysate was analyzed by western blot 24 hours after HIV
infection. iNOS, inducible nitric oxide synthase; ZAP-70, zeta
chain-associated protein kinase 70. b-actin was used as loading
control.cells. On the other hand, dUTP of ingenol-treated MT4
cells was increased by approximately 9% compared with
nontreated cells. Inhibition of apoptosis in HIV-1-
infected T cells enhances virus production and facili-
tates persistent infection [20]. HIV-1einfected and
ingenol-treated MT4 cells suppressed virus production
and early apoptosis arising compared with uninfected
and AZT-treated cells. A reduced level of annexin V
may suggest apoptosis of uninfected and ingenol-
susceptible cells. Otherwise, DNA strand breakages of
HIV-1-infected and ingenol-treated MT4 cells were not
protected from later apoptosis. However, increased level
of dUTP may have been induced by apoptosis of HIV-1
completely infected cells.
Although little is known of the ability of TNF to
induce apoptosis in HIV-infected cells, it may contribute
to apoptosis induced by gp120-mediated cross-linking
of CD4 [21].
TNF-a and p24 antigen production were positively
correlated at 6 days postinfection. In addition, IL-6 was
very slightly increased in HIV-1-infected and ingenol-
treated cells compared with days 1 and 3, suggesting
that elevated TNF-a and IL-6 expression may induce
high levels of HIV-1 infectivity. Indeed, this result is
supported by elevated serum TNF levels seen in symp-
tomatic HIV-infected patients [22,23], but not in
114 K.-J. Hong, et alasymptomatic patients [24,25]. Although the mecha-
nisms to control the apoptotic pathway by ingenol has
not been elucidated in detail, there is evidence that
TNF-a may be involved in regulation of apoptosis
when HIV-infected cells were treated with ingenol
derivatives [26].
The mechanism of anti-HIV-1 activity of ingenol
requires further study. In future, we will focus on
elucidating the steps of HIV-1-mediated immune-related
mechanisms, so as to gain insight into new applications
for anti-HIV treatment.
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